南京生物医药谷50余项产品技术国内外首创 以创新为引擎 全速竞逐医药新赛道 "未来10年，对于脑科学领域是个机遇，比如脑卒中患者有语言障碍，只要戴上一顶'魔法帽'，他的想 法就能变成文字显示出来，这也是我们中心正在孵化的'汉语魔法帽'项目。"程和平院士介绍。 早在今年3月，江北新区揭牌成立"江苏省类脑智能技术创新中心"。该中心由北京大学分子医学南京转 化研究院牵头，联合南京医科大学、南京脑科医院等多方资源，计划用5年时间突破一批前沿科技成 果。 不仅是脑科学领域，在基因与细胞治疗、器官芯片等前沿赛道上，南京生物医药谷也在加速布局，比如 在基因与细胞治疗方面，已打造了涵盖基因检测、诊断、试剂、免疫细胞治疗、CAR-T细胞治疗的全产 业链。本月初，园区企业尧唐生物宣布完成超3亿元B轮融资，公司首席技术官王子君博士表示："处在 药谷这样的产业集群之中，为企业发展带来了很多助力，尧唐生物也得以快速发展。" □ 南京日报/紫金山新闻记者 李都 通讯员 钱钰玲 全球首款全人源BCMA CAR-T细胞治疗1类新药福可苏、全球首创"硒代技术"的1类抗流感新药济可 舒、全球首个且唯一获得NMPA、FDA、CE认证的肿瘤NGS大 ...

5 天前，药捷安康 -B 还是一支港股上市刚刚两个多月的小透明， IPO 后股价表现虽然不错，相比发行价涨了好几倍，但知 名度只局限在创新药的圈子里。后缀带的 B 意思是 Biotechnology ，根据港交所上市规则 18A ，凡是未盈利的生物科技公 司，都得带上这个 B 。 将投中网设为"星标⭐"，第一时间收获最新推送 又没了。 作者丨 张楠 来源丨 投中网 5 天后，也就是 9 月 16 日午间，药捷安康成为全市场的焦点，所有投资群都在问 " 药捷安康是谁 " ？原因过去的这 5 天 里，药捷安康股价从 9 月 10 日开盘的 70.7 港元， 9 月 16 日盘中最高飙升至 679.5 港元，市值最高近 2700 亿港元。 这个市值是什么概念？大约是老牌创新药龙头，市值 1200 亿港元康方生物的 2 倍多、 1600 亿港元信达生物的 1.6 倍，甚 至已经逼近百济神州 3000 亿的港股市值。并且迄今为止，药捷安康还是一家 0 营收，也就是没有产生过任何收入的公司。 药捷安康在 600 多港元的价格足足晃了多半天，截至本文第一次完稿，我都没有想到剧本会走成这样。 9 月 16 日下午 2 点 0 ...

Core Insights - The article highlights the successful launch of two class 1 new drugs, Enzeshushu and Jike Shushu, from companies in the Nanjing Biopharmaceutical Valley, marking a significant achievement in the biopharmaceutical industry [1][2][3] Group 1: Drug Development and Innovation - Jike Shushu, a new anti-influenza drug, was developed in just 6 years, significantly faster than the typical 10-year timeline for class 1 new drugs [2] - Enzeshushu, targeting ovarian cancer, took 17 years from inception to approval, showcasing the long-term commitment required in drug development [3] - The successful development of these drugs reflects a combination of innovation and perseverance, particularly during challenging times such as the COVID-19 pandemic [2][3] Group 2: Supportive Ecosystem - The Nanjing Biopharmaceutical Valley provides essential support services, including regulatory guidance and infrastructure, which facilitate the drug development process for companies [4][5] - The Jiangbei New District has completed nearly 1,800 product technical reviews and over 300 on-site verifications, aiding companies like Xiansheng Pharmaceutical and Reindeer Biotech in accelerating their product launches [5] - The establishment of a public service platform allows startups to access necessary research facilities without the burden of high initial costs, fostering innovation [5] Group 3: Future Prospects - There are currently over 200 class 1 new drugs in development within the biopharmaceutical valley, indicating a robust pipeline for future approvals [5] - The presence of regional technology transfer centers is expected to further enhance the innovation landscape, leading to more new drug developments [5][6] - The Nanjing Biopharmaceutical Valley is becoming a prominent hub for both established and emerging companies, contributing to the growth of the biopharmaceutical industry in the region [6]

Core Insights - The article highlights the rapid development and success of the Nanjing Biopharmaceutical Valley, showcasing the approval of new drugs and the establishment of biotech companies in the region [1][2][4]. Group 1: New Drug Approvals - Nanjing Zhengxiang Pharmaceutical's new flu drug, Jike Shou (Marcelosavir), received approval from the National Medical Products Administration on July 18 [1]. - The antibody drug, Suweishitamon (Enzeshu), developed by Xiansheng Pharmaceutical, was approved just half a month earlier [1]. - The Nanjing Biopharmaceutical Valley has over 200 new drugs in development, with a total of 405 approved drugs, including six new drugs [3]. Group 2: Innovative Drug Development - Jike Shou was developed in just six years, breaking the conventional "three tens" rule of a 10-year development cycle, $1 billion investment, and a success rate below 10% [2]. - The drug demonstrated rapid efficacy, with significant symptom relief achieved in just 23.6 hours during clinical trials [2]. - The success of Zhengxiang Pharmaceutical is attributed to a team of experts returning from the San Francisco Bay Area, focusing on unmet clinical needs in oncology and infectious diseases [2]. Group 3: Company Growth and Listings - Nanjing Weilizhibo Biotechnology successfully listed on the Hong Kong Stock Exchange on July 25, following the earlier listing of Yaojie Ankang [1][5]. - Weilizhibo has developed 14 innovative drug candidates, with six in clinical stages, including the globally leading PD-L1×4-1BB dual antibody [4][5]. - The company’s rapid growth is supported by its pilot production base established in the Biopharmaceutical Valley [5]. Group 4: Ecosystem and Collaboration - The Nanjing Biopharmaceutical Valley fosters a collaborative ecosystem, integrating research, production, and application to support company growth [6][9]. - The establishment of the Nanjing Biopharmaceutical Center has facilitated technology transfer and innovation, with over 1,300 biopharmaceutical companies in the area [6][9]. - The center has partnered with over 100 research institutions and companies, significantly reducing research and development costs [7]. Group 5: Future Development and Urban Integration - The Nanjing Biopharmaceutical Valley aims to become a leading technology city, enhancing living spaces and ecological networks [11]. - Plans include the construction of scenic areas and improved infrastructure to support both innovation and quality of life for residents and professionals [11].

Core Viewpoint - Nanjing Weili Zhizhi Bio-Tech Co., Ltd. successfully listed on the Hong Kong Stock Exchange, raising up to $189 million, marking the second listing in Nanjing Jiangbei New Area this year [1] Company Overview - Founded in 2012, Weili Zhizhi is a clinical-stage biotech company focused on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases [1] - The company has a diverse product portfolio with 14 innovative drug candidates, including 4 core products, all of which are leading in global clinical progress [1] Product Highlights - LBL-024, a dual-targeting antibody drug, is the first and only candidate drug globally to enter the registration clinical stage targeting PD-L1 and 4-1BB [2] - LBL-024's initial indication is for lung neuroendocrine carcinoma, a malignancy with limited effective treatment options [2] - Clinical data shows LBL-024 demonstrates good efficacy and safety in both monotherapy and combination therapy, providing new hope for patients facing treatment challenges [2] - The drug has received breakthrough therapy designation from the National Medical Products Administration and orphan drug status from the FDA for treating neuroendocrine carcinoma [2] - LBL-024 is also approved for clinical research in several other cancers, including small cell lung cancer, cholangiocarcinoma, ovarian cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, liver cancer, and gastric cancer [2] Industry Context - The Nanjing Jiangbei New Area is experiencing rapid development in the life and health industry, with a total of 405 listed drug products, including 6 first-class new drugs [3] - The area is focused on creating an innovative ecosystem for the biopharmaceutical industry, integrating research, production, and application [3]